{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06173362",
            "orgStudyIdInfo": {
                "id": "UCDCC315"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2023-09814",
                    "type": "REGISTRY",
                    "domain": "CTRP (Clinical Trial Reporting Program)"
                },
                {
                    "id": "UCDCC315",
                    "type": "OTHER",
                    "domain": "University of California Davis Comprehensive Cancer Center"
                },
                {
                    "id": "P30CA093373",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/P30CA093373"
                }
            ],
            "organization": {
                "fullName": "University of California, Davis",
                "class": "OTHER"
            },
            "briefTitle": "Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer",
            "officialTitle": "A Pragmatic Phase II Study Evaluating Tolerability in Prostate Cancer Patients Treated With Abiraterone + Prednisone or Darolutamide",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "abiraterone-and-prednisone-or-darolutamide-for-the-treatment-of-advanced-prostate-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-12",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-11-09",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-12-07",
            "studyFirstSubmitQcDate": "2023-12-07",
            "studyFirstPostDateStruct": {
                "date": "2023-12-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-12-07",
            "lastUpdatePostDateStruct": {
                "date": "2023-12-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Mamta Parikh",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "University of California, Davis"
            },
            "leadSponsor": {
                "name": "Mamta Parikh",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This phase II trial compares the effects, good and/or bad of abiraterone and prednisone or darolutamide alone in treating patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Androgens (male hormones) can cause the growth of prostate tumor cells. Abiraterone acetate lowers the amount of androgens made by the body. This may help stop the growth of prostate tumor cells that need androgen to grow. Darolutamide blocks the use of androgens by the tumor cells. Prednisone is used to lessen inflammation and lower the body's immune response. Researchers want to compare the side effects of standard of care (SOC) abiraterone and prednisone or darolutamide alone in treating patients with advanced prostate cancer.",
            "detailedDescription": "PRIMARY OBJECTIVE:\n\nI. Tolerability.\n\nSECONDARY OBJECTIVES:\n\nI. Tolerability in prespecified subpopulations.\n\nII. Prostate-specific antigen (PSA) response at 7 months.\n\nOUTLINE: Patients are assigned to 1 of 2 arms per treating physician preference.\n\nARM I: Patients receive abiraterone and prednisone per SOC. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples during screening and on study.\n\nARM II: Patients receive darolutamide per SOC. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples during screening and on study.\n\nAfter completion of study intervention, patients are followed up for a total of 3 years."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Prostate Adenocarcinoma",
                "Stage III Prostate Cancer AJCC v8",
                "Stage IV Prostate Cancer AJCC v8"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 75,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm I (abiraterone, prednisone)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients receive abiraterone and prednisone per SOC. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples during screening and on study.",
                    "interventionNames": [
                        "Drug: Abiraterone",
                        "Procedure: Biospecimen Collection",
                        "Drug: Prednisone"
                    ]
                },
                {
                    "label": "Arm II (darolutamide)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients receive darolutamide per SOC. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples during screening and on study.",
                    "interventionNames": [
                        "Procedure: Biospecimen Collection",
                        "Drug: Darolutamide"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Abiraterone",
                    "description": "Given abiraterone",
                    "armGroupLabels": [
                        "Arm I (abiraterone, prednisone)"
                    ],
                    "otherNames": [
                        "CB 7598"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Biospecimen Collection",
                    "description": "Undergo collection of blood samples",
                    "armGroupLabels": [
                        "Arm I (abiraterone, prednisone)",
                        "Arm II (darolutamide)"
                    ],
                    "otherNames": [
                        "Biological Sample Collection",
                        "Biospecimen Collected",
                        "Specimen Collection"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Darolutamide",
                    "description": "Given darolutamide",
                    "armGroupLabels": [
                        "Arm II (darolutamide)"
                    ],
                    "otherNames": [
                        "Antiandrogen ODM-201",
                        "BAY 1841788",
                        "BAY-1841788",
                        "BAY1841788",
                        "Nubeqa",
                        "ODM 201",
                        "ODM-201"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Prednisone",
                    "description": "Given prednisone",
                    "armGroupLabels": [
                        "Arm I (abiraterone, prednisone)"
                    ],
                    "otherNames": [
                        ".delta.1-Cortisone",
                        "1, 2-Dehydrocortisone",
                        "Adasone",
                        "Cortancyl",
                        "Dacortin",
                        "DeCortin",
                        "Decortisyl",
                        "Decorton",
                        "Delta 1-Cortisone",
                        "Delta-Dome",
                        "Deltacortene",
                        "Deltacortisone",
                        "Deltadehydrocortisone",
                        "Deltasone",
                        "Deltison",
                        "Deltra",
                        "Econosone",
                        "Lisacort",
                        "Meprosona-F",
                        "Metacortandracin",
                        "Meticorten",
                        "Ofisolona",
                        "Orasone",
                        "Panafcort",
                        "Panasol-S",
                        "Paracort",
                        "Perrigo Prednisone",
                        "PRED",
                        "Predicor",
                        "Predicorten",
                        "Prednicen-M",
                        "Prednicort",
                        "Prednidib",
                        "Prednilonga",
                        "Predniment",
                        "Prednisone Intensol",
                        "Prednisonum",
                        "Prednitone",
                        "Promifen",
                        "Rayos",
                        "Servisone",
                        "SK-Prednisone"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of grade 3 or higher adverse events",
                    "description": "Will be defined and graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0).",
                    "timeFrame": "At 12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Ability to understand and willingness to sign an informed consent form\n* Histologically confirmed prostate adenocarcinoma\n* Advanced prostate cancer appropriate for treatment with abiraterone acetate plus prednisone or darolutamide as assessed by the treating physician\n* Participants are encouraged to be currently treated with androgen deprivation therapy (ADT) or having undergone bilateral orchiectomy\n* Performance status 0 - 2 (Karnofsky \u2265 50%)\n* Age \u2265 18 years at time of consent\n* Life expectancy \u2265 6 months per investigator discretion\n* Ability and stated willingness to adhere to the study visit schedule and other protocol procedures/requirements for the duration of the study\n\nExclusion Criteria:\n\n* Have been on either abiraterone or darolutamide for \\> 28 days prior to initiating enrollment\n* Any condition that in the opinion of the investigator would prohibit the understanding or rendering of informed consent or interfere with the participant's safety or compliance while on trial",
            "healthyVolunteers": false,
            "sex": "MALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "overallOfficials": [
                {
                    "name": "Mamta Parikh",
                    "affiliation": "University of California, Davis",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California Davis Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Sacramento",
                    "state": "California",
                    "zip": "95817",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mamta Parikh",
                            "role": "CONTACT",
                            "phone": "916-734-3772",
                            "email": "mbparikh@ucdavis.edu"
                        },
                        {
                            "name": "Mamta Parikh",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.58157,
                        "lon": -121.4944
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011241",
                    "term": "Prednisone"
                },
                {
                    "id": "D000003348",
                    "term": "Cortisone"
                },
                {
                    "id": "D000000726",
                    "term": "Androgen Antagonists"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                },
                {
                    "id": "D000005938",
                    "term": "Glucocorticoids"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14121",
                    "name": "Prednisone",
                    "asFound": "Prospective",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6569",
                    "name": "Cortisone",
                    "asFound": "Clinical Evaluation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4057",
                    "name": "Androgen Antagonists",
                    "asFound": "Colposcopy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4059",
                    "name": "Androgens",
                    "relevance": "LOW"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9047",
                    "name": "Glucocorticoids",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}